Mesenchymal Stromal Cells for Ischemic Stroke (SAMCIS)

Sean Savitz

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Ischemic Stroke

Treatments: Biological: Placebo Comparator; Biological: MSC Infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT01922908

SAMCIS

Details and patient eligibility

About

The purpose of this study is to determine if mesenchymal stem cells given by IV is feasible and safe in patients with recent ischemic stroke and to decide the maximum tolerated dose when given between 3-10 days after an ischemic stroke.

Full description

This is a randomized, double-blind, placebo controlled study. . Approximately 48 subjects will be enrolled in the trial, undergo a real or SHAM MSC IV infusion and will be follow out to 1 year. There will potentially be 4 Cohorts with the dose escalation at a 3:1 randomization schedule

Objectives:

• The primary hypothesis' are that intravenous administration of allogeneic bone marrow derived mesenchymal stem cells is feasible and safe in patients with recent ischemic stroke and to determine the maximum tolerated dose (MTD) of IV MSCs when administered sub-acutely between 3-10 days following ischemic stroke.
• The secondary hypothesis is that allogeneic MSC transplantation will improve functional outcome after recent ischemic stroke.

Safety and clinical efficacy points to be evaluated at Day 7 clinic visit, Day 30, Day 60, Day 90, and Day 180. Primary outcome or Primary endpoint of the study is to define the safety or harm of the MSCs

Sex: All

Ages: 18 to 83 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. acute ischemic stroke
2. age 18 to 83 years
3. post stroke mRS > 3
4. NIHSS of 7-25
5. Deficits on the total NIHSS can be lower than 7 provided the patients have moderate aphasia or visual loss (2 on the Best Language or Visual loss NIHSS subcomponent) *Criteria for mRS not used for this category of subjects
6. Last seen normal st within 3-9 days prior to stroke. Time of onset for wake-up stroke will be defined as the time the patient woke up with symptoms.
7. stem cell transplantation procedure must be performed between 3-10 days after stroke symptom onset

Exclusion criteria

1. Ischemic stroke, primary hemorrhagic or traumatic lesion of the brain or myocardial infarction within past 30 days prior to current stroke.
2. Mechanical heart valve
3. Uncontrolled seizure disorder, defined as a seizure within the last 6 months
4. Developmental delay
5. Chronic kidney disease
6. Hepatic disease or altered liver function
7. Pulmonary disease
8. Cancer within 5 years prior to study
9. Prior immunosuppression, including chemotherapy within last 3 years
10. Known HIV
11. Uncorrected coagulopathy or severe anemia
12. Pregnancy
13. Unable to undergo MRI or CT scan
14. Imaging shows clinically significant hemorrhage

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

MSC infusion

Active Comparator group

Description:

Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset

Treatment:

Biological: MSC Infusion

SHAM infusion

Placebo Comparator group

Description:

Infusion of normal saline placebo

Treatment:

Biological: Placebo Comparator